Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect

Murphy, Ana A.; Morales, Arlene J.; Kettel, L. Michael; Yen, S. S. C.

doi:10.1016/s0015-0282(16)57678-x

Cited by 164 publications

(62 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reduction in uterine size after treatment with the P-blocking drug RU-486 is similar to that found with GnRH-a (33). A prospective, randomized, controlled trial using either 5 or 10 mg of RU-486 for 1 year found that both doses induced a 48% decrease in mean uterine volume after 6 months.…”

Section: Progesterone-mediated Medical Treatmentsupporting

confidence: 54%

Uterine myomas: management

Parker¹

2007

Fertility and Sterility

200

128

View full text Add to dashboard Cite

Section: Progesterone-mediated Medical Treatmentsupporting

confidence: 54%

Uterine myomas: management

Parker¹

2007

Fertility and Sterility

200

128

View full text Add to dashboard Cite

“…Treatment with the progesterone antagonist RU-486 (mifepristone) has been reported to induce the regression of leiomyomas, accompanied by a reduction in progesterone receptor immunoreactivity, thus suggesting a direct antiprogesterone effect. [15][16][17] Tori et al 18 reported a case demonstrating multiple benign metastasizing leiomyomas, with the expression of both estrogen and progesterone receptors, which was successfully treated with a GnRH agonist. Although there has not been any reported association of leiomyoma growth with the effect of progesterone in any other organs except the uterus, these fi ndings support the view that progester- In our case, an elevation of serum progesterone with primary aldosteronism was observed at admission.…”

Section: Discussionmentioning

confidence: 99%

Multiple solitary leiomyomas in the esophagus: Report of a case

et al. 2011

View full text Add to dashboard Cite

We herein report our findings for an asymptomatic 65-year-old man presenting with multiple solitary leiomyomas in the esophagus, who was undergoing follow-up for primary aldosteronism with high levels of serum progesterone. Esophageal endoscopy and computed tomography showed multiple submucosal tumors with calcification in the thoracic esophagus. A subtotal esophagectomy was performed because the possibility of malignancy could not be ruled out based on a needle biopsy taken of the specimen. The final resected specimen showed eight solitary, encapsulated nodules between the middle and lower thoracic esophagus. Histopathological examinations showed these nodules to have the typical histological findings of leiomyomas. In addition, staining with antibodies against the progesterone receptor revealed diffuse expression in the nuclei of the leiomyoma cells. Only four cases with more than eight solitary leiomyomas have been reported, including the current case. However, this is the first reported case where primary aldosteronism with elevated serum progesterone levels has been implicated in the pathogenesis of multiple solitary leiomyomas in the esophagus.

show abstract

“…A number of clinical trials have investigated the efficacy and safety of SPRMs as a treatment for fibroids, showing that mifepristone (118)(119)(120), UPA (74,75,(118)(119)(120)(121), asoprisnil (122,123), and telapristone acetate (73) are all effective in reducing fibroid and uterine volume (73). Fibroid volumes are reduced by 17%-57% and uterine volume by 9%-53% following treatment with SPRMs compared with placebo (74).…”

Section: Selective Progesterone Receptor Modulatorsmentioning

confidence: 99%